CVRx Inc (NASDAQ: CVRX) is a commercial-stage medical device company that develops, manufactures, and commercializes implantable neuromodulation devices for patients with cardiovascular disease. Revenue comes from transactional sales of its Barostim implantable device system to hospitals and cardiac care centers. Barostim is the first FDA-approved medical technology using neuromodulation to improve symptoms in heart failure patients, delivering electrical pulses to baroreceptors in the carotid artery to modulate the autonomic nervous system. CVRx operates as a single-product commercial company, with Barostim holding FDA approval in the United States as the primary marketed product as of the 10-K filed February 13, 2026.

Revenue model

Transactional device sales. CVRx generates revenue by selling Barostim implantable device systems, primarily to hospitals and implanting physicians. No subscription or recurring revenue model is described in the filing excerpts.

Products and services

Barostim: an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, FDA-approved for treatment of heart failure symptoms via neuromodulation.

Customers and end markets

Hospitals and cardiac care centers implanting devices in patients diagnosed with heart failure. End market is cardiovascular disease, specifically heart failure.

Value-chain role

Medical device manufacturer and direct commercial seller of implantable neuromodulation systems for cardiovascular indications.

Geographic exposure

United States, where Barostim holds FDA approval. No additional geographic detail is supported by the filing excerpts provided.

Source: SEC 10-K, filed 2026-02-13

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Accelerate Diagnostics, Inc Accuray Inc Apyx Medical Inc Apollo Endosurgery, Inc. Owlet Inc RetinalGenix Technologies Inc Sensus Healthcare Inc Tactile Systems Technology Inc Stereotaxis Inc